Unknown PHASE4 INTERVENTIONAL 2-arm NCT03377335

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes

Sponsor: AstraZeneca

Interventions Dapagliflozin 10mg Metformin

Updated 7 times since 2018 Last updated: Feb 22, 2018 Started: Dec 22, 2017 Primary completion: Dec 31, 2018 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Type 2 Diabetes Mellitus, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2020 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Jan 2020 [monthly]

Active Not Recruiting PHASE4

▶ Show 2 earlier versions

Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE4

Status: Not Yet Recruiting → Active Not Recruiting
Jan 2018 — Mar 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of Catania
University of Palermo

Data source: University of Palermo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palermo, Italy